24/7 Wall Street
11 Aug 2026, 16:50 UTC · 3h ago
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
11 Aug 2026, 16:50 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Legend Biotech achieved its first-ever quarter of company-wide profitability with net income of $33.2 million. — Crossing the threshold to profitability is a major fundamental de-risking event for biotech companies, often triggering significant valuation reratings.
+0.80CARVYKTI net sales grew 50% year-over-year to $657 million, with management reiterating peak annual sales targets above $5 billion. — Strong growth in the primary revenue driver validates the commercial ramp and supports long-term bullish valuation models.
+0.70Legend Biotech reported a 100% overall response rate for its investigational therapy LB2501, with a U.S. IND filing planned by year-end. — Positive early clinical data reduces the 'single-product' risk by proving the pipeline's potential beyond CARVYKTI.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
The company maintains a strengthened balance sheet with approximately $965 million in cash and no long-term debt. — High liquidity and zero debt provide a safety cushion and funding for R&D without the need for immediate dilutive financing.
+0.40The company is currently led by interim CEO Alan Bash following the departure of Ying Huang last month. — Leadership transitions create operational uncertainty and can lead analysts to trim price targets until a permanent CEO is named.
-0.20Which stocks this story touches
The company reported its first-ever profitable quarter with a significant revenue beat and strong sales growth for CARVYKTI.
Positive outlook for CARVYKTI, which is co-developed by JNJ, with peak sales targets exceeding $5 billion.
Mentioned as a competitor in the CAR-T space facing competitive positioning debates against LEGN.
Partnered with Legend Biotech on the LB2102 program, providing a strategic pipeline expansion.
The article mentions Intel is upsizing its stock offering, which typically implies dilution or a need for capital.
Mentioned only as a historical reference point for an analyst's past success.
[mutual] Legend Biotech and Johnson & Johnson co-develop the CAR-T therapy CARVYKTI.
[mutual] Both companies compete in the multiple myeloma CAR-T space with CARVYKTI and Abecma respectively.
[mutual] The LB2102 DLL3-targeted CAR-T program is licensed to Novartis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Seeking Alpha
4h ago
